Rifampicin for multiple system atrophy

The Lancet Neurology

Volumn 13, Issue 3, 2014, Pages 237-239

  Wenning, Gregor K ^a   Krismer, Florian ^a   Poewe, Werner ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FEMALE; HUMANS; MALE; MULTIPLE SYSTEM ATROPHY; RIFAMPIN;

EID: 84894287346     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70022-5     Document Type: Note

References (16)

1. Graham JG, Oppenheimer DR Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 1969, 32:28-34.
2. Quinn N Multiple system atrophy-the nature of the beast. J Neurol Neurosurg Psychiatry 1989, 1(suppl):78-89.
3. Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013, 12:264-274. for The European Multiple System Atrophy Study Group.
4. Papp MI, Kahn JE, Lantos PL Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989, 94:79-100.
5. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 1998, 251:205-208.
6. Low PA, Robertson D, Gilman S, et al. Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014, published online Feb 5. http://dx.doi.org/10.1016/S1474-4422(13)70301-6.
7. Ubhi K, Rockenstein E, Mante M, et al. Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy. Neuroreport 2008, 19:1271-1276.
8. Fellner L, Wenning GK, Stefanova N Models of multiple system atrophy. Curr Top Behav Neurosci 2013, published online Dec 14. 10.1007/7854_2013_269.
9. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014, 370:311-321.
10. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014, 370:322-333.
11. A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease. JAMA Neurol 2013, 70:25-33. HORIZON Investigators of the Huntington Study Group, European Huntington's Disease NetworkEuropean Huntington's Disease Network.
12. Berg D, Lang AE, Postuma RB, et al. Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol 2013, 12:514-524.
13. Geser F, Wenning GK, Seppi K, et al. Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Mov Disord 2006, 21:179-186.
14. Seppi K, Schocke MF, Mair KJ, et al. Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study. NeuroImage 2006, 31:240-245.
15. Eberling JL, Dave KD, Frasier MA α-synuclein imaging: a critical need for Parkinson's disease research. J Parkinsons Dis 2013, 3:565-567.
16. Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med 2013, 369:233-244. Multiple-System Atrophy Research Collaboration.